ArticleTherapeutics and clinical risk management2009
Long-term efficacy and safety of anastrozole for adjuvant treatment of early breast cancer in postmenopausal women.
Article in Therapeutics and clinical risk management, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A prospective, randomized study on hepatotoxicity of anastrozole compared with tamoxifen in women with breast cancer.Cancer science · 2014Trial
- The role of exercise in aromatase inhibitor-induced arthralgia.PM & R : the journal of injury, function, and rehabilitation · 2024Review
- Investigation of genotoxicity risk and DNA repair capacity in breast cancer patients using anastrozole.Northern clinics of Istanbul · 2018Article
- 17α-ethynyl-5α-androstane-3α, 17β-diol treatment of MNU-induced mammary cancer in rats.International journal of breast cancer · 2011Article
- Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.Journal of medicinal chemistry · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For more than 20 years, tamoxifen has been the gold standard for the adjuvant treatment of postmenopausal women with hormone-responsive early breast cancer. However, recent randomized trials have shown efficacy and tolerability benefits with the third-generation aromatase inhibitor anastrozole, resulting in an increased use of this agent in the adjuvant setting. Data on anastrozole's long-term efficacy and tolerability are therefore of interest in clinical practice and will be reviewed here, especially in the light of the 100-month analysis of the ATAC (Anastrozole, Tamoxifen Alone or in Combination) trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.